8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Dec 2, 2025·SEC
Material company update
Nov 14, 2025·SEC
Benitec Biopharma Inc.(BNTC)Earnings, Financials & Key Ratios
BNTC•NASDAQ
$12.14
$416M mkt cap·Price updated May 7, 2026
AboutBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.Show more
- Revenue$0
- EBITDA-$42M-87.4%
- Net Income-$38M-74.3%
- EPS (Diluted)-1.05+60.8%
- ROE-52.46%+42.8%
- Debt/Equity0.01+45.2%
BNTC Key Insights
Benitec Biopharma Inc. (BNTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BNTC Price & Volume
Benitec Biopharma Inc. (BNTC) stock price & volume — 10-year historical chart
Loading chart...
BNTC Growth Metrics
Benitec Biopharma Inc. (BNTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-137.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.3%
Return on Capital
10 Years-172.72%
5 Years-273.01%
3 Years-374.66%
Last Year-57.58%
BNTC Recent Earnings
Benitec Biopharma Inc. (BNTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q1 2026Latest
Feb 12, 2026EPS
$0.26
Est $0.23
-13.0%
Revenue
—
Q4 2025
Nov 14, 2025EPS
$0.22
Est $0.35
+37.1%
Revenue
—
Q4 2025
Sep 22, 2025EPS
$0.42
Est $0.28
-50.0%
Revenue
$556,000
Q2 2025
May 14, 2025EPS
$0.24
Est $0.36
+33.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $0.26vs $0.23-13.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.22vs $0.35+37.1% | — |
| Q4 2025 | Sep 22, 2025 | $0.42vs $0.28-50.0% | $556,000 |
| Q2 2025 | May 14, 2025 | $0.24vs $0.36+33.3% | — |
Based on last 12 quarters of dataView full earnings history →
BNTC Peer Comparison
Benitec Biopharma Inc. (BNTC) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 QURE | 1.49B | 24.15 | -6.98 | -40.64% | -11.54% | -145.81% | 2.70 | |
 SLDB | 550.63M | 7.07 | -3.55 | -73.63% | 0.12 | |||
 DTIL | 95.95M | 7.48 | -2.06 | -50.12% | -98.7% | -81.24% | 0.31 | |
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 |
Compare BNTC vs Peers
Benitec Biopharma Inc. (BNTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNTC Income Statement
Benitec Biopharma Inc. (BNTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 450.31K | 455.45K | 11.32M | 97K | 59K | 73K | 75K | 0 | 0 | 556K |
| Revenue Growth % | 29.96% | 1.14% | 2384.77% | -99.14% | -39.18% | 23.73% | 2.74% | -100% | - | - |
| Cost of Goods Sold | 209.02K | 331.3K | 426.51K | -185K | 123K | 9K | 381K | 343K | 396K | 562.52K |
| COGS % of Revenue | 46.42% | 72.74% | 3.77% | -190.72% | 208.47% | 12.33% | 508% | - | - | - |
| Gross Profit | 241.29K▲ 0% | 124.15K▼ 48.5% | 10.89M▲ 8672.1% | 282K▼ 97.4% | -64K▼ 122.7% | 64K▲ 200.0% | -306K▼ 578.1% | -343K▼ 12.1% | -396K▼ 15.5% | -6.52K▲ 0% |
| Gross Margin % | 53.58% | 27.26% | 96.23% | 290.72% | -108.47% | 87.67% | -408% | - | - | -1.17% |
| Gross Profit Growth % | -0.58% | -48.55% | 8672.15% | -97.41% | -122.69% | 200% | -578.13% | -12.09% | -15.45% | - |
| Operating Expenses | 4.4M | 8.68M | 8.99M | 8.56M | 13.53M | 17.92M | 18.77M | 22.25M | 41.37M | 55.57M |
| OpEx % of Revenue | 977.99% | 1905% | 79.42% | 8827.84% | 22935.59% | 24545.21% | 25033.33% | - | - | - |
| Selling, General & Admin | 6.99M | 6.41M | 6.66M | 5.57M | 6.51M | 6.65M | 6M | 6.65M | 23.43M | 34.68M |
| SG&A % of Revenue | 1552.22% | 1407.42% | 58.84% | 5739.18% | 11037.29% | 9104.11% | 8001.33% | - | - | - |
| Research & Development | 5.32M | 5.06M | 2.17M | 3M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M | 20.61M |
| R&D % of Revenue | 1181.74% | 1111.29% | 19.21% | 3093.81% | 11898.31% | 15441.1% | 17032% | - | - | - |
| Other Operating Expenses | -7.91M | 735 | 154.77K | -5K | 0 | 0 | 0 | 0 | -396K | 278K |
| Operating Income | -15.92M▲ 0% | -8.55M▲ 46.3% | 2M▲ 123.4% | -8.28M▼ 513.4% | -13.6M▼ 64.2% | -17.85M▼ 31.3% | -19.08M▼ 6.9% | -22.6M▼ 18.4% | -41.77M▼ 84.8% | -55.57M▲ 0% |
| Operating Margin % | -3536.22% | -1877.75% | 17.7% | -8537.11% | -23044.07% | -24457.53% | -25441.33% | - | - | -9994.96% |
| Operating Income Growth % | 36.21% | 46.29% | 123.42% | -513.44% | -64.18% | -31.32% | -6.87% | -18.43% | -84.82% | - |
| EBITDA | -15.76M | -8.41M | 2.16M | -7.91M | -13.17M | -17.46M | -18.7M | -22.25M | -41.7M | -55.55M |
| EBITDA Margin % | -3499.19% | -1846.46% | 19.07% | -8151.55% | -22325.42% | -23920.55% | -24933.33% | - | - | -9991.27% |
| EBITDA Growth % | -17.43% | 46.63% | 125.66% | -466.45% | -66.59% | -32.57% | -7.09% | -19.01% | -87.35% | -134% |
| D&A (Non-Cash Add-back) | 166.75K | 142.51K | 154.77K | 374K | 424K | 392K | 381K | 343K | 69.33K | 20.52K |
| EBIT | -4.36M | -8.73M | 2.58M | -8.28M | -13.88M | -18.18M | -19.53M | -21.75M | -41.77M | -55.04M |
| Net Interest Income | 0 | 0 | 122K | 62K | -6K | -32K | -33K | 904K | 3.29M | 2.87M |
| Interest Income | 0 | 0 | 122K | 62K | 0 | 0 | 0 | 904K | 3.29M | 2.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 6K | 32K | 33K | 0 | 0 | 0 |
| Other Income/Expense | 11.55M | 179.24K | 606.03K | 7K | -286K | -354K | -481K | 847K | 3.85M | 4.24M |
| Pretax Income | -4.37M▲ 0% | -8.55M▼ 95.6% | 2.87M▲ 133.5% | -8.27M▼ 388.6% | -13.88M▼ 67.8% | -18.21M▼ 31.2% | -19.56M▼ 7.4% | -21.75M▼ 11.2% | -37.92M▼ 74.3% | -50.9M▲ 0% |
| Pretax Margin % | -970.99% | -1877.42% | 25.34% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | -9154.88% |
| Income Tax | 0 | 1.47K | -864.22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.02% | -30.14% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.37M▲ 0% | -8.55M▼ 95.6% | 2.87M▲ 133.5% | -8.27M▼ 388.6% | -13.88M▼ 67.8% | -18.21M▼ 31.2% | -19.56M▼ 7.4% | -21.75M▼ 11.2% | -37.92M▼ 74.3% | -50.9M▲ 0% |
| Net Margin % | -970.99% | -1877.42% | 25.34% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | -9154.88% |
| Net Income Growth % | 76.37% | -95.56% | 133.53% | -388.58% | -67.78% | -31.16% | -7.44% | -11.19% | -74.32% | -137.69% |
| Net Income (Continuing) | -4.37M | -8.55M | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M | -50.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -63.56▲ 0% | -103.61▼ 63.0% | 28.45▲ 127.5% | -69.09▼ 342.9% | -27.27▲ 60.5% | -19.31▲ 29.2% | -14.12▲ 26.9% | -2.68▲ 81.0% | -1.05▲ 60.8% | -1.11▲ 0% |
| EPS Growth % | 80.83% | -63.02% | 127.46% | -342.89% | 60.53% | 29.19% | 26.88% | 81.02% | 60.82% | 29.3% |
| EPS (Basic) | -63.56 | -103.61 | 28.45 | -69.09 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 | - |
| Diluted Shares Outstanding | 137.6K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.28M | 36.21M | 45.97M |
| Basic Shares Outstanding | 137.59K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.26M | 36.21M | 45.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BNTC Balance Sheet
Benitec Biopharma Inc. (BNTC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.03M | 15.35M | 18.73M | 10.81M | 20.61M | 4.82M | 3.73M | 51.67M | 98.52M | 189.59M |
| Cash & Short-Term Investments | 13.43M | 11.84M | 15.82M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M | 188.79M |
| Cash Only | 13.35M | 11.82M | 15.7M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M | 188.79M |
| Short-Term Investments | 76.84K | 22.04K | 126.76K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.39M | 3.03M | 2.54M | 59K | 25K | 3K | 55K | 229K | 33K | 130K |
| Days Sales Outstanding | 2.74K | 2.43K | 81.79 | 222.01 | 154.66 | 15 | 267.67 | - | - | 28.39 |
| Inventory | -65.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 281K | 385.66K | 1K | 87K | 15K | 14K | 13K | 579K | 741K | 675K |
| Total Non-Current Assets | 387.3K | 326.16K | 478.33K | 935K | 771K | 1.15M | 735K | 536K | 1.07M | 1.09M |
| Property, Plant & Equipment | 341.96K | 234.33K | 469.23K | 769K | 577K | 993K | 613K | 449K | 991K | 1.02M |
| Fixed Asset Turnover | 1.32x | 1.94x | 24.12x | 0.13x | 0.10x | 0.07x | 0.12x | - | - | 0.56x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 45.34K | 91.82K | 9.1K | 9K | 194K | 160K | 122K | 87K | 83K | 314K |
| Total Assets | 17.42M▲ 0% | 15.68M▼ 10.0% | 19.21M▲ 22.5% | 11.74M▼ 38.9% | 21.38M▲ 82.0% | 5.97M▼ 72.1% | 4.46M▼ 25.3% | 52.21M▲ 1069.6% | 99.59M▲ 90.8% | 190.68M▲ 0% |
| Asset Turnover | 0.03x | 0.03x | 0.59x | 0.01x | 0.00x | 0.01x | 0.02x | - | - | 0.00x |
| Asset Growth % | 17.26% | -10% | 22.53% | -38.86% | 82.04% | -72.06% | -25.26% | 1069.58% | 90.75% | 872.98% |
| Total Current Liabilities | 864.51K | 1.87M | 2.64M | 1.14M | 1.37M | 2.53M | 3.98M | 4.92M | 1.8M | 2.8M |
| Accounts Payable | 133.71K | 426.06K | 1.47M | 282K | 274K | 422K | 1.14M | 1.35M | 201K | 1.85M |
| Days Payables Outstanding | 233.49 | 469.4 | 1.26K | -556.38 | 813.09 | 17.11K | 1.09K | 1.44K | 185.27 | 446.9 |
| Short-Term Debt | 0 | 0 | 0 | 192K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 158.3K | 1.82M | 1.09M | 459K | 276K | 400K | 1.82M | 475K | 1.25M | 483K |
| Current Ratio | 19.70x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x | 54.67x |
| Quick Ratio | 19.77x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x | 54.67x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -418.51 |
| Total Non-Current Liabilities | 26.89K | 35.26K | 0 | 370K | 0 | 559K | 284K | 38K | 495K | 519K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 213K | 0 | 559K | 284K | 0 | 495K | 2.03M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 157K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 26.89K | 35.26K | 0 | 0 | 0 | 0 | 0 | 38K | 0 | -403K |
| Total Liabilities | 891.4K | 1.91M | 2.64M | 1.51M | 1.37M | 3.09M | 4.26M | 4.96M | 2.3M | 3.32M |
| Total Debt | 0 | 0 | 0 | 405K | 213K | 811K | 559K | 284K | 849K | 987K |
| Net Debt | -13.35M | -11.82M | -15.7M | -9.4M | -19.56M | -3.25M | -1.92M | -50.58M | -96.89M | -187.8M |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | -7.27x | - | - | - | - | - | - | 3.38x |
| Interest Coverage | - | - | - | - | -2266.00x | -557.94x | -578.21x | - | - | - |
| Total Equity | 16.53M▲ 0% | 13.77M▼ 16.7% | 16.57M▲ 20.3% | 10.24M▼ 38.2% | 20.01M▲ 95.4% | 2.88M▼ 85.6% | 202K▼ 93.0% | 47.25M▲ 23290.1% | 97.3M▲ 105.9% | 187.36M▲ 0% |
| Equity Growth % | 17.48% | -16.68% | 20.34% | -38.21% | 95.45% | -85.6% | -92.99% | 23290.1% | 105.92% | 1046.92% |
| Book Value per Share | 120.11 | 83.42 | 82.20 | 42.61 | 19.80 | 1.50 | 0.15 | 4.60 | 2.69 | 4.08 |
| Total Shareholders' Equity | 16.53M | 13.77M | 16.57M | 10.24M | 20.01M | 2.88M | 202K | 47.25M | 97.3M | 187.36M |
| Common Stock | 119.56M | 120.54M | 1K | 1K | 1K | 0 | 0 | 1K | 2K | 3K |
| Retained Earnings | -104.32M | -107.86M | -108.87M | -116.64M | -130.12M | -148.33M | -167.89M | -190.26M | -228.18M | -248.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.29M | 1.1M | -1.86M | -1.95M | -1.46M | -1.25M | -830K | -892K | -839K | -883K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTC Cash Flow Statement
Benitec Biopharma Inc. (BNTC) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.3M | -8.55M | 4.79M | -7.54M | -12.83M | -15.9M | -18.01M | -19.4M | -23.59M | -23.59M |
| Operating CF Margin % | -1844.06% | -1877.42% | 42.33% | -7768.04% | -21749.15% | -21779.45% | -24016% | - | - | - |
| Operating CF Growth % | 58.91% | -2.97% | 156.02% | -257.31% | -70.3% | -23.9% | -13.29% | -7.72% | -21.57% | -30.56% |
| Net Income | -4.37M | -8.55M | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M | -50.9M |
| Depreciation & Amortization | 217K | 0 | 158K | 374K | 424K | 392K | 381K | 343K | 396K | 462K |
| Stock-Based Compensation | 386K | 0 | 957.2K | 237K | 634K | 870K | 452K | 830K | 17.43M | 15.16M |
| Deferred Taxes | -819.52K | 0 | -957.2K | 0 | 0 | 0 | -714K | 0 | 0 | 0 |
| Other Non-Cash Items | -4.47M | 0 | 700K | 2K | -16K | 10K | 717K | 1K | -764K | 9.39M |
| Working Capital Changes | 760K | 0 | 1.32M | 126K | 8K | 1.04M | 714K | 1.17M | -2.73M | -4.79M |
| Change in Receivables | 0 | 0 | 607K | 2.4M | 28K | 1K | -50K | -176K | 197K | 130.13K |
| Change in Inventory | 0 | 0 | 0 | -700K | -83K | -1.09M | -1.31M | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 740K | -1.7M | 55K | 1.09M | 1.36M | 0 | -2.38M | -5.11M |
| Cash from Investing | -232.07K | -107.98K | -399.19K | -94K | -221K | -13K | -1K | -179K | -18K | -17.47K |
| Capital Expenditures | -131.41K | -60.97K | -403.39K | -95K | -221K | -13K | -1K | -179K | -18K | -29.47K |
| CapEx % of Revenue | 29.18% | 13.39% | 3.56% | 97.94% | 374.58% | 17.81% | 1.33% | - | - | - |
| Acquisitions | 0 | 0 | 4K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 30.33K | -47.01K | 202 | 0 | 0 | 0 | 0 | 0 | 0 | 12K |
| Cash from Financing | 6.1M | 6.25M | -688.12K | 1.77M | 22.52M | 0 | 16.02M | 68.03M | 70.48M | 130.92M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.74M | -229.93K | -688.12K | -480K | -3.23M | 0 | -1.87M | -2.85M | 0 | 100.15M |
| Net Change in Cash | -657.02K▲ 0% | -947.62K▼ 44.2% | 4.43M▲ 567.5% | -5.92M▼ 233.6% | 9.97M▲ 268.5% | -15.71M▼ 257.6% | -1.59M▲ 89.9% | 48.44M▲ 3154.2% | 46.93M▼ 3.1% | 110.56M▲ 0% |
| Free Cash Flow | -8.44M▲ 0% | -8.61M▼ 2.1% | 4.39M▲ 150.9% | -7.63M▼ 273.9% | -13.05M▼ 71.1% | -15.91M▼ 21.9% | -18.01M▼ 13.2% | -19.58M▼ 8.7% | -23.61M▼ 20.5% | -18.76M▲ 0% |
| FCF Margin % | -1873.24% | -1890.81% | 38.76% | -7865.98% | -22123.73% | -21797.26% | -24017.33% | - | - | -3373.94% |
| FCF Growth % | 58.78% | -2.09% | 150.94% | -273.94% | -71.07% | -21.9% | -13.2% | -8.71% | -20.55% | 14.77% |
| FCF per Share | -61.31 | -52.17 | 21.76 | -31.75 | -12.92 | -8.28 | -13.00 | -1.91 | -0.65 | -0.65 |
| FCF Conversion (FCF/Net Income) | 1.90x | 1.00x | 1.67x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x | 0.37x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTC Key Ratios
Benitec Biopharma Inc. (BNTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -28.58% | -56.45% | 18.9% | -61.73% | -91.79% | -159.08% | -1268.61% | -91.68% | -52.46% | -27.17% |
| Return on Invested Capital (ROIC) | -658.42% | -250.17% | 106.24% | -723.56% | -1573.61% | -31507.06% | - | - | - | 3231.55% |
| Gross Margin | 53.58% | 27.26% | 96.23% | 290.72% | -108.47% | 87.67% | -408% | - | - | -1.17% |
| Net Margin | -970.99% | -1877.42% | 25.34% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | -9154.88% |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | - | -2266.00x | -557.94x | -578.21x | - | - | - |
| FCF Conversion | 1.90x | 1.00x | 1.67x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x | 0.37x |
| Revenue Growth | 29.96% | 1.14% | 2384.77% | -99.14% | -39.18% | 23.73% | 2.74% | -100% | - | - |
BNTC SEC Filings & Documents
Benitec Biopharma Inc. (BNTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BNTC Frequently Asked Questions
Benitec Biopharma Inc. (BNTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Benitec Biopharma Inc. (BNTC) reported $0.6M in revenue for fiscal year 2025. This represents a 2% increase from $0.5M in 2013.
Benitec Biopharma Inc. (BNTC) grew revenue by 0.0% over the past year. Growth has been modest.
Benitec Biopharma Inc. (BNTC) reported a net loss of $50.9M for fiscal year 2025.
Dividend & Returns
Benitec Biopharma Inc. (BNTC) has a return on equity (ROE) of -52.5%. Negative ROE indicates the company is unprofitable.
Benitec Biopharma Inc. (BNTC) had negative free cash flow of $18.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More BNTC
Benitec Biopharma Inc. (BNTC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates